Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MDH2 | P40926 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27142999 | 0.94 | CTSV (0.53) | CTSVCTSLALDH1A1HSD17B10USP2 | |
| SCHEMBL31498185 | 0.88 | NR4A2 (0.58) | CTSVCTSLALDH1A1HSD17B10USP2 | |
| SCHEMBL30710231 | 0.83 | TUBB4A (0.49) | CTSVCTSLALDH1A1HSD17B10USP2 | |
| SCHEMBL27027505 | 0.81 | GPR17 (0.53) | ALDH1A1HSD17B10USP2HPGDMAOA | |
| SCHEMBL6824331 | 0.78 | MAOB (0.56) | CTSVCTSLALDH1A1HSD17B10HPGD | |
| SCHEMBL2433763 | 0.77 | MDH2 (0.69) | ALDH1A1HPGDSMN1; SMN2MDH2NPC1 | |
| SCHEMBL19127960 | 0.76 | KDM4E (0.58) | CTSVCTSLALDH1A1HPGDSMN1; SMN2 | |
| Potassium Ion SCHEMBL31498179 | 0.76 | CTSV (0.54) | CTSVCTSLALDH1A1HSD17B10HPGD | |
| SCHEMBL8406972 | 0.76 | FLT3 (0.70) | CTSVCTSLALDH1A1HSD17B10HPGD | |
| SCHEMBL7256169 | 0.75 | CTSV (0.66) | CTSVCTSLALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547668-A1 | BIFUNCTIONAL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE BIFUNCTIONAL COMPOUND, AND METHOD FOR TREATING ANDROGEN RECEPTOR RELATED DISEASE BY USING THE SAME | Anhorn Medicines Co., Ltd. (TW) | 2025-05-07 | — | — | EP | disclosed |
| US-20240336620-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | ANHORN MEDICINES CO., LTD. (TW) | 2024-10-10 | — | — | US | disclosed |
| US-20240018149-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | ANHORN MEDICINES CO., LTD. (TW) | 2024-01-18 | — | — | US | disclosed |
| US-20240018149-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | ANHORN MEDICINES CO., LTD. (TW) | 2024-01-18 | — | — | US | disclosed |
| WO-2024002205-A1 | BIFUNCTIONAL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE BIFUNCTIONAL COMPOUND, AND METHOD FOR TREATING ANDROGEN RECEPTOR RELATED DISEASE BY USING THE SAME | ANHORN MEDICINES CO., LTD. (CN) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024002289-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | ANHORN MEDICINES CO., LTD. (CN) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336620-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | CRBN, UBQLN2, CBL | CTSV 998/4885CTSL 2036/4885ALDH1A1 3876/4885 |
| US-20240018149-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | MDM2, PSMG3, ADRM1 | CTSV 387/4885CTSL 1252/4885ALDH1A1 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.